---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-248138"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:32:18.650458+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Equillium announces Ono option lapse; pauses EQUATOR enrollment to review acceleration; cash runway into Q4 2025

## Summary
- Ono's option to acquire itolizumab (EQ001) lapsed; Equillium retains all commercial rights to itolizumab.
- EQUATOR Phase 3 study enrollment paused; company plans to accelerate topline data to Q1 2025 with ~150 patients.
- Over 150 patients enrolled to date; orphan drug and fast track designations for first-line acute GVHD remain.
- Biocon SA completed Phase 2 study of itolizumab in ulcerative colitis; topline data expected Q1 2025.
- Company pauses EQ101 and EQ302 activities; cash runway expected into Q4 2025 with accelerated EQUATOR.

## SEC filing metadata
- accession: 0001193125-24-248138
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312524248138/0001193125-24-248138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312524248138/d787967d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-248138
- JSON: https://secwatch.observer/filing/0001193125-24-248138.json
- Plain text: https://secwatch.observer/filing/0001193125-24-248138.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.